Cort Johnson, founder of Healthrising.org, recently teamed up with neuroscientist Joshua Grant of Mendus.org to complete a six-week, 144 person study titled entitled “The influence of MitoQ on symptoms and cognition in fibromyalgia, myalgic encephalomyelitis and chronic fatigue.”
Please note, this is a study, also called observational research, and is not a clinical trial. This study was conducted outside of government clinical trial guidelines, has not been peer reviewed, and was not published in a scientific journal. SMCI does not endorse the results of this study and is sharing it for informational purposes only.
The study evaluated the impacts of the antioxidant MitoQ, which targets mitochondria, on patients in three groups. According to the study, MitoQ helped reduce pain in patients with fibromyalgia but had little effect on patients with ME/CFS.
“There were both encouraging and disappointing results. MitoQ seems to work quite well for fibromyalgia, lowering pain and improving memory. For ME/CFS the higher dosage showed no effects that could not be explained by placebo. However, our open label cohort (Group 3) showed huge effects with the lower dose. Interestingly, those effects did not match the placebo effects suggesting there is more to the story,” said Dr. Grant in the Business Wire report about the study.
To read the study results on Health Rising visit: http://www.healthrising.org/blog/2016/08/08/mendus-fibromyalgia-chronic-fatigue-syndrome-mitoq-coq10-trial/
TO read the announcement on Business Wire visit: http://www.businesswire.com/news/home/20160815005778/en/
